A lawsuit claims AHN and Highmark deployed the Abridge AI recording tool without notifying patients, violating privacy rights; the case could force health systems to secure explicit consent and may prompt regulators to clarify HIPAA coverage for AI‑generated data.
What Happened
A Pittsburgh‑area woman has filed a lawsuit in Allegheny County Common Pleas Court on October 30, 2026, alleging that Allegheny Health Network (AHN) and Highmark failed to properly inform her that their clinical rooms use an artificial‑intelligence recording tool called Abridge.
The complaint claims that the use of Abridge violated the patient’s right to privacy and trust.
The lawsuit states that AHN began deploying Abridge in 2024, expanding the tool to roughly 400 providers across more than 40 specialties. Highmark added the same technology in August 2025 at its hospitals and outpatient locations.
Once a conversation is used to train a model, it cannot be taken back, the complaint notes.
According to the filing, the plaintiff and class members “have lost the ability to trust that what they tell their doctors stays private.” The complaint further asserts that the patients “suffered distress knowing their health information was handed to a stranger and used to build that stranger’s technology. They paid for confidential care they did not receive. And their information now sits with a third party, indefinitely and outside their control.”
Abridge, a multibillion‑dollar company, is reported to be used by more than 300 health systems that collectively serve over 250 million patients. In June 2025, Abridge AI Inc. was valued at $5.3 billion, nearly double what it had been four months earlier, the plaintiff says.
The plaintiff, a former Pittsburgh Post‑Gazette reporter who spent nearly 17 years there and was part of a Pulitzer Prize‑winning team, is also the author of Death by Cyanide. She can be reached at pward@triblive.com.
What This Means For You
If you are a patient receiving care at AHN or Highmark, you should verify whether your provider uses Abridge or a similar AI recording tool.
Because the lawsuit claims that the tool was deployed without proper notification, you may want to request a copy of the privacy notice that explains how your data will be used and stored.
Patients who have already had conversations recorded by Abridge should consider requesting a copy of the recordings and any transcripts generated.
The complaint notes that once a conversation is used to train a model, it cannot be taken back, so you may want to explore whether the provider can delete or anonymize your data from the system.
Healthcare organizations that use Abridge should review their consent procedures to ensure they meet the standards implied by the lawsuit. The complaint highlights that the lack of notification “violated the woman’s sense of trust and control,” suggesting that clearer disclosure could mitigate future legal risk.
If you are a provider or administrator at a health system, you should assess whether your current AI tools require explicit patient consent. The lawsuit indicates that the absence of such consent can lead to claims of privacy violations and loss of patient trust.
Why It Matters
This lawsuit underscores the growing tension between AI adoption in clinical settings and patient privacy expectations. While AI tools like Abridge promise improved documentation and workflow efficiency, they also raise questions about data ownership and control.
The case could prompt broader scrutiny of how health systems disclose AI usage to patients and whether existing privacy regulations adequately cover AI‑generated data.
Moreover, the legal challenge may influence how other health systems approach AI deployment. If courts side with the plaintiff, providers might need to implement more robust consent mechanisms or reconsider the use of third‑party AI services that retain patient data indefinitely.
From a regulatory perspective, the lawsuit highlights a gap in current health privacy laws: they often address human‑to‑human interactions but may not explicitly cover AI‑mediated recordings. This could spur lawmakers to clarify the scope of HIPAA and state privacy statutes regarding AI tools.
Key Takeaway
- Abridge is used by over 300 health systems, serving more than 250 million patients.
- AHN deployed Abridge in 2024; Highmark added it in August 2025.
- Once a conversation is used to train a model, it cannot be taken back.
- Patients may need to request deletion or anonymization of their data from AI systems.
Frequently Asked Questions
What is Abridge?
Abridge is an artificial‑intelligence recording tool that captures and transcribes clinical conversations. It is used by more than 300 health systems and was valued at $5.3 billion in June 2025.
How does the lawsuit affect my privacy?
The complaint alleges that patients were not properly notified that their conversations were recorded and used to train AI models. If the court finds in favor of the plaintiff, it could set a precedent that requires explicit patient consent for such recordings.
Can I get my recordings deleted?
The lawsuit claims that once a conversation is used to train a model, it cannot be taken back. However, patients may still request that their data be removed or anonymized from the system, depending on the provider’s policies.
Leave a Reply